---
title: "Multimodal AI Models Predict Response to Venetoclax and Azacitidine in Newly Diagnosed AML"
id: "medrxiv-12-multimodal-artificial-intelligence-fusion-models-to-predict-response-to"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-12-multimodal-artificial-intelligence-fusion-models-to-predict-response-to"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.12.26364938v1?rss=1"
published_at: "2026-10-14T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Multimodal AI Models Predict Response to Venetoclax and Azacitidine in Newly Diagnosed AML
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-12-multimodal-artificial-intelligence-fusion-models-to-predict-response-to
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.12.26364938v1?rss=1)
- **Published At:** 2026-10-14T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators trained two multimodal fusion models combining clinical, genetic and image data to predict best response to **venetoclax and azacitidine** in newly diagnosed **acute myeloid leukemia** (AML) patients. - The models were a custom ResNet-34–based architecture and a pathology foundation model fine-tuned on **bone marrow smear** (BMS) images. - Training used 193 patients who received venetoclax plus azacitidine; the authors reported AUROCs of 0.79 and 0.82 for the ResNet and fine-tuned foundation models in a held-out test set. - External validation returned AUROCs of 0.76 and 0.73 for the two models, respectively. - Sensitivity analyses reported that fusing image, clinical and genetic modalities outperformed models trained on any single modality alone. - In uni- and multivariable analyses, image-based classification acted as an independent predictive marker, second in effect size only to **IDH1/2** mutation status, and it outperformed other genetic alterations. - Explainability maps showed high model attention on myeloblasts, indicating cell-specific morphological features linked to response that are not captured by genetics alone. - Training and internal testing data were exempted from IRB review at UC Denver; external validation used data approved by a German ethics committee (ethical vote No.7972_BO_K_2018). - The manuscript is a preprint and has not completed peer review; data are available on reasonable request to the corresponding author.
## Clinical Analysis & Structured Key Points
Multimodal Artificial Intelligence Fusion Models to Predict Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia | medRxiv Skip to main content Multimodal Artificial Intelligence Fusion Models to Predict Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia View ORCID Profile Jan-Niklas Eckardt , View ORCID Profile Ishan Srivastava , View ORCID Profile Kellen Gill , Andrea Abeyta Osypuk , View ORCID Profile Zenggang Pan , View ORCID Profile Mohamed Benouis , View ORCID Profile Martin M.K. Schneider , View ORCID Profile Freya Schulze , View ORCID Profile Susann WInter , View ORCID Profile Katja Sockel , View ORCID Profile Martin Bornhaeuser , View ORCID Profile Rabia Shahswar , Michael Heuser , View ORCID Profile Jan Moritz Middeke , View ORCID Profile Daniel Pollyea doi: https://doi.org/10.64898/2026.10.12.26364938 Jan-Niklas Eckardt 1 Department of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Jan-Niklas Eckardt For correspondence: jan-niklas.eckardt{at}uniklinikum-dresden.de Ishan Srivastava 1 Department of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Ishan Srivastava Kellen Gill 2 University of Colorado; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Kellen Gill Andrea Abeyta Osypuk 3 Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Zenggang Pan 3 Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Zenggang Pan Mohamed Benouis 4 University Hospital Carl Gustav Carus TUD Dresden University of Te; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Mohamed Benouis Martin M.K. Schneider 1 Department of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Martin M.K. Schneider Freya Schulze 1 Department of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Freya Schulze Susann WInter 1 Department of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Susann WInter Katja Sockel 1 Department of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Katja Sockel Martin Bornhaeuser 1 Department of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Martin Bornhaeuser Rabia Shahswar 5 Department of Hematology, Hemostasis, Oncology and Cell Therapy, Hannover Medical School, Hannover, Germany; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Rabia Shahswar Michael Heuser 6 Department of Internal Medicine IV, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, Halle, Germany; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jan Moritz Middeke 1 Department of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Jan Moritz Middeke Daniel Pollyea 7 Division of Hematology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Daniel Pollyea Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Venetoclax and azacitidine (ven-aza) is a standard of care therapy for newly diagnosed acute myeloid leukemia (AML) patients unfit to receive intensive therapy, and may also be appropriate for certain fit patients. Models predicting response to ven-aza currently focus predominantly on genetics. Here, we present two multimodal fusion models: a custom ResNet-34-based model and a pathology foundation model fine-tuned for bone marrow smear (BMS) images that combine clinical and genetic variables with whole slide images. Training on 193 newly diagnosed AML patients who received ven-aza, we obtained an area-under-the-receiver-operating-characteristic (AUROC) of 0.79 and 0.82 for the ResNet-based and fine-tuned foundation models in a heldout test set, and 0.76 and 0.73 in an external validation set, predicting best response to this therapy. Sensitivity analysis showed that fusing image data with clinical and genetic variables outperformed training on either modality alone. In univariable and multivariable analyses, image-based classification was an independent predictive marker, second only in effect size to IDH1/2 mutation status, outperforming other genetic alterations. Image-based explainability showed high model attention on myeloblasts, suggesting previously unrecognized cell-specific patterns associated with response. Our findings suggest BMS images complement genetic biomarkers to refine outcome prediction in ven-aza treatment and incentivize AI-supported outcome prediction, including bone marrow morphology. Competing Interest Statement J-NE declares consulting services for AstraZeneca, Novartis, and Johnson & Johnson, holds shares in Cancilico, has received an institutional research grant by Novartis, and has received honoraria by Amgen, Astellas, AstraZeneca, Johnson & Johnson, Novartis, Pfizer and Servier. JMM declares consulting services for Johnson & Johnson, Roche, Gilead, Abbvie, Jazz, Pfizer, Astellas, Novartis, AstraZeneca, Clycostem, holds shares in Cancilico and Synagen, has received institutional research grants by Johnson & Johnson, Jazz and Novartis; and has received honoraria by Novartis, Roche, Johnson & Johnson, Abbvie, Pfizer, Sanofi, Astellas and Beigene. MH declares honoraria from Astellas, Daiichi Sankyo, Otsuka, Pfizer, and Servier, paid consultancy for Abbvie, Ascentage Pharma, Astellas, Daiichi Sankyo, Janssen, Miltenyi, and Servier, and research funding to his institution from Abbvie, Bayer Pharma AG, Jazz Pharmaceuticals, Glycostem, PinotBio, Servier, and Toray. The other authors declare no conflict of interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Training and internal testing data was deemed exempt from institutional review board (IRB) review by the IRB of UC Denver, Colorado, USA. Retrospective analysis for external validation data coming from the German Ven/Aza registry was approved by the local Ethics Review Committee (ethical vote No.7972_BO_K_2018), for the Hannover Medical School, Hannover, Germany. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data are available upon reasonable request to the corresponding author. Funder Information Declared Deutsche Krebshilfe , 70117128 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted October 14, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Multimodal Artificial Intelligence Fusion Models to Predict Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Multimodal Artificial Intelligence Fusion Models to Predict Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia Jan-Niklas Eckardt , Ishan Srivastava , Kellen Gill , Andrea Abeyta Osypuk , Zenggang Pan , Mohamed Benouis , Martin M.K. Schneider , Freya Schulze , Susann WInter , Katja Sockel , Martin Bornhaeuser , Rabia Shahswar , Michael Heuser , Jan Moritz Middeke , Daniel Pollyea medRxiv 2026.10.12.26364938; doi: https://doi.org/10.64898/2026.10.12.26364938 Share This Article: Copy Citation Tools Multimodal Artificial Intelligence Fusion Models to Predict Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia Jan-Niklas Eckardt , Ishan Srivastava , Kellen Gill , Andrea Abeyta Osypuk , Zenggang Pan , Mohamed Benouis , Martin M.K. Schneider , Freya Schulze , Susann WInter , Katja Sockel , Martin Bornhaeuser , Rabia Shahswar , Michael Heuser , Jan Moritz Middeke , Daniel Pollyea medRxiv 2026.10.12.26364938; doi: https://doi.org/10.64898/2026.10.12.26364938 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (628) Allergy and Immunology (914) Anesthesia (343) Cardiovascular Medicine (4923) Dentistry and Oral Medicine (488) Dermatology (421) Emergency Medicine (667) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1655) Epidemiology (16115) Forensic Medicine (35) Gastroenterology (1227) Genetic and Genomic Medicine (7167) Geriatric Medicine (740) Health Economics (1079) Health Informatics (5179) Health Policy (1452) Health Systems and Quality Improvement (1807) Hematology (595) HIV/AIDS (1362) Infectious Diseases (except HIV/AIDS) (16396) Intensive Care and Critical Care Medicine (1187) Medical Education (684) Medical Ethics (156) Nephrology (733) Neurology (7435) Nursing (372) Nutrition (1110) Obstetrics and Gynecology (1274) Occupational and Environmental Health (1020) Oncology (3687) Ophthalmology (1077) Orthopedics (400) Otolaryngology (461) Pain Medicine (488) Palliative Medicine (142) Pathology (714) Pediatrics (1837) Pharmacology and Therapeutics (744) Primary Care Research (780) Psychiatry and Clinical Psychology (6032) Public and Global Health (9882) Radiology and Imaging (2479) Rehabilitation Medicine and Physical Therapy (1495) Respiratory Medicine (1258) Rheumatology (654) Sexual and Reproductive Health (791) Sports Medicine (591) Surgery (792) Toxicology (109) Transplantation (313) Urology (299)
## Related Clinical Research

- [Pope Leo XIV Diagnosed with Lung Adenocarcinoma: Key Insights](https://medichelpline.com/clinical-feed/medical-news-today-0-pope-leo-lung-cancer-diagnosis-what-to-know-about-lung-adenocarcinoma.md)
- [Runx1–Gata2 Axis in Hematopoiesis: Epigenetic Control of Lineage Fate](https://medichelpline.com/clinical-feed/pubmed-42801378.md) (DOI: 10.1007/s11033-026-12742-6)
- [Cellular Metabolism, Immunity, and Oncogenesis: Drug Discovery Opportunities](https://medichelpline.com/clinical-feed/frontiers-in-immunology-5-editorial-cellular-metabolism-the-immune-system-and-oncogenesis-opportunities.md)
- [Structured aerobic exercise linked to lower cancer recurrence and improved survival](https://medichelpline.com/clinical-feed/medical-news-today-0-aerobic-exercise-could-help-improve-outlook-after-cancer-treatment.md)
- [Sellas Phase 3 REGAL trial for galinpepimut-S faces delays and likely negative outcome in AML](https://medichelpline.com/clinical-feed/stat-news-1-stat-a-sellas-immunotherapy-study-long-delayed-will-end-in-failure.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.